胞肌治疗视神经萎缩

Cytoinosine in treatment of optic atrophy

目的 :观察胞肌对视神经萎缩的治疗修复作用。方法 :视神经萎缩病人 60例 (男性 4 9例 ,女性 11例 ,38a±s14a)随机分为 2组 (每组 30例 ) ,胞肌组给予注射用胞肌 30 0mg ,妥拉唑林组给予妥拉唑林 2 5mg ,均球后注射给药 ,qod× 6wk。分别测定用药前后的视力、视野、视诱发电位 (VEP)。结果 :胞肌组的总有效率 70 % ,妥拉唑林组为 13% ,差异有非常显著意义 (P <0 .0 1) ;治疗后临床各项指标的恢复率为视力 >视野 >VEP ;对各种原因引起视神经萎缩的疗效以视网膜色素变性所致的视神经萎缩有效率最高 ( 86% ) ,其次是视神经炎后视神经萎缩 ( 53% ) ,遗传性的视神经萎缩效果较差 ,青光眼和钝挫伤引起视神经萎缩因病例太少未予分析。结论 :胞肌是一种有效治疗视神经萎缩的药物 。

AIM: To investigate the restorative efficacy of cytoinosine in the treatment of optic atrophy. METHODS: Sixty patients with optic atrophy (M49, F11; age 38 a±s14 a) were randomly divided into 2 groups (30 for each group). The cytoinosine group received cytoinosine 300 mg and the control group received tolazoline 25 mg, qod for 6 wk. All patients were given the drug with retrobulbar injections. Visual acuity, visual fields and visual evoked potential (VEP) were measured pre and posttherapy respectively. RESULTS:The total effective rate in the cytonosine group (70%) was much better than that in the control group (13%, P<0.01). The response rate for optic atrophy caused by retinitis pigmentosa and optic neuritis were 86% and 53% respectively, and that for hereditary optic atrophy was lower. Among the evaluating criteria, visual acuity repairing took the largest part of the proportion, following was the visual field improving and the VEP improving took the smallest part. CONCLUSION:Cytoinosine is an effective drug in the treatment of optic atrophy without obvious adverse reactions.